Lisinopril dihydrate: Precision ACE Inhibitor for Hypertension and Cardiovascular Research

Executive Summary: Lisinopril dihydrate (C21H35N3O7·2H2O, MW 441.52 g/mol) is a long-acting angiotensin converting enzyme (ACE) inhibitor with an IC₅₀ of 4.7 nM, validated for use in hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy research (Tieku & Hooper 1992). It is a lysine analogue of MK 421, acts by blocking ACE-mediated conversion of angiotensin I to II, and thus modulates the renin-angiotensin-aldosterone system (RAAS). The dihydrate form, offered by APExBIO, provides robust solubility in aqueous media (≥2.46 mg/mL with gentle warming/ultrasonics) and is confirmed to ≥98% purity via mass spectrometry and NMR (APExBIO). Lisinopril dihydrate enables fine-tuned, reproducible control of blood pressure in experimental models, standing as a benchmark for selectivity and reproducibility in ACE inhibition workflows. Recent comparative research confirms its lack of off-target peptidase inhibition at pharmacologically relevant concentrations (Tieku & Hooper 1992).

Biological Rationale

The renin-angiotensin system (RAS) is central to blood pressure regulation and fluid balance. Angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor and aldosterone stimulator (Tieku & Hooper 1992). Overactivation of RAS is a major contributor to hypertension, heart failure, and renal dysfunction. Inhibition of ACE directly reduces angiotensin II and aldosterone levels, increases plasma renin activity, and induces vasodilation and natriuresis. Lisinopril, a lysine derivative of MK 421, is widely used in research to dissect the RAS and its role in cardiovascular and renal disease models. The availability of the dihydrate form (see Lisinopril dihydrate) ensures consistent dosing and solubility, facilitating controlled mechanistic studies.

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate functions as a competitive inhibitor of ACE. It binds the active site of ACE, which is a zinc-dependent dipeptidyl carboxypeptidase, thereby preventing the cleavage of the C-terminal dipeptide from angiotensin I to generate angiotensin II. The compound demonstrates a potent IC₅₀ of 4.7 nM under standard assay conditions (APExBIO Certificate of Analysis). By reducing angiotensin II formation, it also suppresses aldosterone secretion, decreases vasoconstriction, and lowers blood pressure. Additionally, increased bradykinin levels may contribute to vasodilation. Unlike some other inhibitors, lisinopril dihydrate does not significantly inhibit related peptidases such as aminopeptidase A, N, or W at clinically relevant concentrations, supporting its target selectivity (Tieku & Hooper 1992).

Evidence & Benchmarks

• Lisinopril dihydrate inhibits ACE activity with an IC₅₀ of 4.7 nM in biochemical assays (APExBIO, product page).
• It does not significantly inhibit aminopeptidase A (AP-A), N (AP-N), or W (AP-W) at concentrations selective for ACE inhibition (Tieku & Hooper 1992).
• The dihydrate form is insoluble in ethanol but soluble in water at ≥2.46 mg/mL with gentle warming and ultrasonication (APExBIO, specifications).
• Purity is confirmed at ≥98% by mass spectrometry and NMR, supporting reproducibility in sensitive research workflows (APExBIO, QC data).
• In comparative inhibitor studies, carboxyalkyl ACE inhibitors like lisinopril are shown to have minimal off-target activity relative to sulfhydryl-containing ACE inhibitors (Tieku & Hooper 1992).

Applications, Limits & Misconceptions

Lisinopril dihydrate is extensively used to model hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy in preclinical research (Tieku & Hooper 1992). It enables mechanistic dissection of the renin-angiotensin system and blood pressure regulation pathways. The compound's high purity and solubility support sensitive cell-based and in vivo models, as detailed in Lisinopril Dihydrate: Precision ACE Inhibition for Hypertension Workflows—this article provides expanded comparative data and updated selectivity insights beyond existing protocols.

Common Pitfalls or Misconceptions

• Lisinopril dihydrate does not inhibit aminopeptidase A, N, or W at concentrations used for ACE inhibition (Tieku & Hooper 1992).
• It is insoluble in ethanol and should be dissolved in water with gentle warming and sonication for maximum solubility (APExBIO, specs).
• Active solutions are unstable for long-term storage; only reconstitute immediately prior to use to prevent degradation (APExBIO guidance).
• Lisinopril dihydrate is not an appropriate model for non-ACE-mediated blood pressure regulation mechanisms.
• It does not model the effects of sulfhydryl-containing ACE inhibitors, which may have distinct off-target profiles (Tieku & Hooper 1992).

Workflow Integration & Parameters

Lisinopril dihydrate is supplied as a solid and should be stored desiccated at room temperature. For use, dissolve in sterile water (≥2.46 mg/mL) with gentle warming and ultrasonic treatment. Avoid prolonged storage of solutions; prepare fresh before use. Shipping is on blue ice to ensure stability during transit (APExBIO, product page). For comparative protocols and troubleshooting, consult Lisinopril Dihydrate: ACE Inhibitor Workflows for Hypertension Models, which focuses on workflow troubleshooting, whereas this article details molecular selectivity and updated evidence.

Quality control includes mass spectrometry and NMR validation, and each lot is supplied with a Certificate of Analysis. APExBIO’s Lisinopril dihydrate (SKU B3290) is widely referenced as a benchmark standard in translational cardiovascular and renal research. For further mechanistic insights, see Lisinopril Dihydrate: Mechanistic Insights and Novel Paradigms, which expands on signaling and emerging research models; this article extends the discussion with specific focus on selectivity, application boundaries, and recent comparative inhibitor studies.

Conclusion & Outlook

Lisinopril dihydrate remains a gold-standard, long-acting ACE inhibitor for research into hypertension, heart failure, myocardial infarction, and diabetic nephropathy. Its validated selectivity, high purity, and robust solubility parameters ensure reproducible results and minimize confounding off-target effects. APExBIO provides detailed QC and handling support, anchoring the reliability of the B3290 product for advanced RAS pathway dissection. Ongoing research will further refine application protocols and expand the compound’s use in precision cardiovascular and renal models.